基于磁共振成像的前列腺癌主动监测五年结局:大型队列研究
该研究纳入672例接受主动监测的前列腺癌患者,采用以mpMRI为主导的监测方案并省略协议活检。中位随访58个月,3年和5年分别有84.7%和71.8%患者继续主动监测,无前列腺癌相关死亡,转移率低;基线MRI可见病灶或次要Gleason模式4与更早接受治疗相关。
要点
- 以MRI为主导的主动监测可避免常规活检,5年继续监测率为71.8%。
- 基线MRI可见病灶或次要Gleason模式4者更可能转为积极治疗。
- 无前列腺癌相关死亡,转移发生率低,安全性可比标准主动监测。
核心结论
- 以MRI为主导的监测方案在停药率、死亡率和转移率方面与标准主动监测相当。
- 基线MRI可见病灶和/或次要Gleason分级4与5年内更可能转为积极治疗相关。
研究设计与样本
- 回顾性队列研究,纳入2004年8月至2017年11月期间672例接受主动监测的前列腺癌患者。
- 纳入标准为Gleason 3+3或3+4局限期前列腺癌、前列腺特异性抗原<20 ng/ml且有基线mpMRI。
- 中位随访58个月(四分位距37-82个月),累计超过3800人年。
主要发现
- 3年和5年分别有84.7%(95%CI 82.0-87.6)和71.8%(95%CI 68.2-75.6)患者继续主动监测。
- 共216例接受治疗,24例死亡且均非前列腺癌相关(6.3/1000人年,95%CI 4.1-9.5)。
- 8例发生转移(2.1事件/1000人年,95%CI 1.0-4.3),27例随访活检升级至Gleason≥4+3(7.7事件/1000人年,95%CI 5.2-11.3)。
- 基线MRI可见病灶(Likert 4-5)或次要Gleason模式4者无事件生存率和无治疗生存率更低(log-rank检验 p<0.001)。
临床怎么用
- 对于低危前列腺癌患者,可考虑采用以MRI为主导的主动监测方案以减少常规活检。
- 基线MRI可见病灶或次要Gleason模式4的患者应更密切监测,因其更可能转为积极治疗。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the use of multiparametric magnetic resonance imaging (mpMRI) in active surveillance (AS) for prostate cancer is of increasing interest, existing data are derived from small cohorts. OBJECTIVE: We describe clinical, histological, and radiological outcomes from an established AS programme, where protocol-based biopsies were omitted in favour of MRI-led monitoring. DESIGN, SETTING, AND PARTICIPANTS: Data on 672 men enrolled in AS between August 2004 and November 2017 (inclusion criteria: Gleason 3 + 3 or 3 + 4 localised prostate cancer, presenting prostate-specific antigen <20 ng/ml, and baseline mpMRI) were collected from the University College London Hospital (UCLH) database. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary outcomes were event-free survival (EFS; event defined as prostate cancer treatment, transition to watchful waiting, or death) and treatment-free survival (TFS). Secondary outcomes included rates of all-cause or prostate cancer-related mortality, metastasis, and upgrading to Gleason ≥4 + 3. Data on radiological and histological progression were also collected. RESULTS AND LIMITATIONS: More than 3800 person-years (py) of follow-up were accrued (median: 58 mo; interquartile range 37-82 mo). Approximately 84.7% (95% confidence interval [CI]: 82.0-87.6) and 71.8% (95% CI: 68.2-75.6) of patients remained on AS at 3 and 5 yr, respectively. EFS and TFS were lower in those with MRI-visible (Likert 4-5) disease or secondary Gleason pattern 4 at baseline (log-rank test; p < 0.001). In total, 216 men were treated. There were 24 deaths, none of which was prostate cancer related (6.3/1000 py; 95% CI: 4.1-9.5). Metastases developed in eight men (2.1 events/1000 py; 95% CI: 1.0-4.3), whereas 27 men upgraded to Gleason ≥4 + 3 on follow-up biopsy (7.7 events/1000 py; 95% CI: 5.2-11.3). CONCLUSIONS: The rates of discontinuation, mortality, and metastasis in MRI-led surveillance are comparable with those of standard AS. MRI-visible disease and/or secondary Gleason grade 4 at baseline are associated with a greater likelihood of moving to active treatment at 5 yr. Further research will concentrate on optimising imaging intervals according to baseline risk. PATIENT SUMMARY: In this report, we looked at the outcomes of magnetic resonance imaging (MRI)-based surveillance for prostate cancer in a UK cohort. We found that this strategy could allow routine biopsies to be avoided. Secondary Gleason pattern 4 and MRI visibility are associated with increased rates of treatment. We conclude that MRI-based surveillance should be considered for the monitoring of small prostate tumours.
引用
- Stavrinides V, Giganti F, Trock B, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol. 2020. PMID: 32360049. doi:10.1016/j.eururo.2020.03.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。